经济观察网泰恩康（301263）2026年将有多项关键事件值得关注，涉及公司治理、产品管线及市场动 态。 公司多个仿制药和创新药预计在2026年取得重要进展。复方硫酸钠片(国内首仿)与和胃整肠丸(国内独 家)的本地化生产注册均预计在2026年上半年获批。老花眼用药盐酸毛果芸香碱滴眼液(国内首仿)预计在 2026年下半年获批。此外，创新药CKBA乳膏针对儿童白癜风的II期临床试验计划于2026年第一季度启 动首例患者入组，并计划同期向FDA申报。 股票近期走势 2026年1月28日，公司发布《2026年员工持股计划(草案)》，拟向不超过145名员工实施股权激励，并设 定了2026年至2028年的业绩考核目标。其中，2026年营业收入目标值为10.00亿元，考核利润目标值为 3.00亿元。 产品研发进展 公司于2025年12月15日被纳入中证1000指数拟生效样本范围，市场预期其有望被纳入相关ETF的被动配 置范畴，可能对股票流动性产生长期影响。2026年2月2日，公司控股股东郑汉杰和孙伟文部分股份质 押，合计质押股份占公司总股本的13.81%，公告称此举为个人资金需要。2026年2月13日，泰恩康股价 上涨2. ...

Company and Industry Summary Company: 心玮医疗 (Xinwei Medical) Key Points - **2025 Revenue Forecast**: The company expects revenue for 2025 to be between 400 million to 410 million yuan, representing a year-on-year growth of over 43.9% [1] - **Profitability Improvement**: The company anticipates a pre-tax profit of 80 million yuan in 2025, a significant turnaround from a pre-tax net loss of 12 million yuan in 2024 [1] - **Revenue Growth Drivers**: The revenue increase is attributed to the collaborative growth of three main product lines: ischemic, hemorrhagic, and interventional pathways. New products and technologies in the ischemic stroke field are being applied, leading to a steady increase in market share for various ischemic stroke products [1] - **Commercial Sales Expansion**: The company has achieved large-scale commercial sales of intracranial stents in the hemorrhagic stroke sector, with other product sales also experiencing growth. Additionally, sales of interventional pathway products continue to rise, contributing to the overall revenue expansion [1] Additional Insights - **Cost Management**: The company has effectively controlled sales and administrative costs, leading to a reduction in expense ratios and an improvement in profitability [2] - **Product Registration**: The application for the self-expanding intracranial drug-eluting stent has been accepted by the NMPA, marking a significant milestone as there are currently no similar products available globally. The company's R&D progress is considered to be at the forefront of the industry [2] - **Product Pipeline Expansion**: The acceptance of the registration application signifies an enhancement of the company's product pipeline in the treatment of vascular stenosis, with ongoing deepening of technological layout [3]